home / stock / phrm:cc / phrm:cc news

PHRM:CC News and Press, Pharmather Holdings Ltd.

Stock Information
Company Name: Pharmather Holdings Ltd.
Stock Symbol: PHRM:CC
Market: CNQC
Website: pharmather.com
Menu
PHRM:CC PHRM:CC Quote PHRM:CC Short PHRM:CC News PHRM:CC Articles PHRM:CC Message Board
Get PHRM:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
PHRM:CC - PharmaTher's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent ...
PHRM:CC - PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine

TORONTO, May 10, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced receipt of an Amendment Acknowledgment Letter (“AAL”) for its Priority Origi...

PHRM:CC - PharmaTher's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine

TORONTO, May 01, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent ...

PHRM:CC - Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, i...
PHRM:CC - PharmaTher's Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia

TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent...

PHRM:CC - PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

TORONTO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its Priority Original Abbreviated New Drug Application (“ANDA”) for K...

PHRM:CC - PharmaTher Provides Update for Expected FDA Approval of Ketamine

TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, is pleased to provide an update for the Company’s lead drug, ketamine (“KETARX™ ...
PHRM:CC - PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX(TM) (Ketamine)

FDA assigns GDUFA goal date of April 29, 2024 Milestone builds upon PharmaTher’s commitment toward unlocking the potential of ketamine for unmet medical needs TORONTO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “Pharma...

PHRM:CC - PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX(TM) (Ketamine) to the FDA

TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce it has submitted a priority original Abbreviated New Drug Appl...

PHRM:CC - PharmaTher Announces Positive Research Results for PharmaPatch(TM) with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics

TORONTO, July 18, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce that it has successfully completed a research study evaluating ...
Next 10